Optimal choice of neoadjuvant therapy for HER2-positive breast cancer. Analysis of doctors’ preferences in Russian Federation

E. V. Artamonova; E. V. Lubennikova

Medical alphabet
Medicinskij alfavit

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

User

eng | рус

Medical alphabet

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Artamonova E.V., Lubennikova E.V. Optimal choice of neoadjuvant therapy for HER2-positive breast cancer. Analysis of doctors’ preferences in Russian Federation. Medical alphabet. 2023;(27):7-12. (In Russ.) https://doi.org/10.33667/2078-5631-2023-27-7-12

Views PDF (Rus): 191

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles Editors' Choice

Editor-in-Chief

Petrikov Sergey S.

Subscription Login to verify subscription

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

E. V. Artamonova
National Medical Research Centre of Oncology n. a. N. N. Blokhin; Russian National Research Medical University n. a. N. I. Pirogov; Moscow Regional Research Clinical Institute n. a. M. F. Vladimirsky
Russian Federation

Artamonova Elena V., DM Sci (habil.), head of Dept of Antitumor Drug Therapy No. 1, Dept of Drug Treatment; professor at Dept of Oncology and Radiation Therapy; head of Dept of Oncology and Thoracic Surgery

Moscow.

E. V. Lubennikova
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation

Lubennikova Elena V., PhD Med, senior researcher at Dept of Antitumor Drug Therapy No.1

Moscow.

Notifications

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Medical alphabet

For citations:

Cookies policy